Compare Biogen Inc (BIIB) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Procter & Gamble Co — how do they compare? Biogen Inc trades at $196.49 (market cap $28.34B), while Procter & Gamble Co trades at $147.81 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 12× Biogen Inc's market cap, and Procter & Gamble Co pays a 2.92% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PG | |
|---|---|---|
Market Cap | $28.34B | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $167.18 |
52-Week Low | $122.68 | $138.10 |
Enterprise Value | $30.62B | $365.64B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Procter & Gamble (PG) trades at $147.89, down 0.32% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $1.42. Revenue reached $84.28B in 2025, with a net income margin of 19.16%. Recent news highlights PG's dividend reliability and supply chain enhancements, though some analysts question its premium valuation amid modest growth outlooks.
PG offers stable dividend income with 69 consecutive years of increases, but faces near-term headwinds from premium valuations and soft demand. The consensus price target of $161.71 suggests upside potential, supported by efficient cash flow generation. Key risks include economic sensitivity and competitive pressures, yet institutional holdings reflect confidence in long-term resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
